Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort pMDI versus formoterol Turbuhaler for exacerbation reduction in COPD
2014-000593-19Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of budesonide and formoterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Rate of moderate and severe COPD exacerbations. Started Jun 2014; status: completed.
02
Drugs
budesonideformoterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-000593-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000593-19.